File sBLA for F8 tesamorelin formulation and multi-dose pen injector
Deadline passed; outcome being checked
- Announced
- 25 Feb 2021
- Due
- 30 Jun 2022
- Status
- Checking
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Theratechnologies plans to file an sBLA for the F8 formulation and multi-dose pen injector in early 2022 for the treatment of lipodystrophy in people living with HIV.”
What we found
The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory other
- Indicative materiality
- Medium rules
- Action
- File
- Deliverable
- sBLA for F8 formulation and multi-dose pen injector
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- Medium
Tell me what happens
This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- OutcomeNot yet assessed. Nothing is judged before the deadline.
Are you Theratechnologies Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C512717-024487 · Corrections policy